Загрузка...
505. Bezlotoxumab Reduces Recurrence of Clostridium difficile Infection in Immunocompromised Patients: Early Experience at a Tertiary Care Center
BACKGROUND: Bezlotoxumab (BEZ) was approved in 2017 for prevention of recurrent C. difficile infection (CDI), with a number needed to treat (NNT) of 10 reported in the registration trials. Little information is available on its effectiveness in high-risk populations. BEZ was added to the institution...
Сохранить в:
| Опубликовано в: : | Open Forum Infect Dis |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6253614/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.514 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|